Technical Analysis for ALLR - Allarity Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.58 | -3.99% | -0.02 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | -3.99% | |
Narrow Range Bar | Range Contraction | -3.99% | |
Inside Day | Range Contraction | -3.99% | |
Wide Bands | Range Expansion | -3.99% |
Alert | Time |
---|---|
Possible NR7 | 4 days ago |
Down 5% | 4 days ago |
60 Minute Opening Range Breakdown | 4 days ago |
Down 3% | 4 days ago |
Fell Below Previous Day's Low | 4 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/15/2023
Allarity Therapeutics, Inc. Description
Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Health Sciences Drugs Treatment Of Cancer Enzymes Protein Kinase Inhibitor Tyrosine Kinase Doxorubicin Liposome
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 269.8 |
52 Week Low | 0.55 |
Average Volume | 4,558,121 |
200-Day Moving Average | 11.47 |
50-Day Moving Average | 2.76 |
20-Day Moving Average | 0.84 |
10-Day Moving Average | 0.66 |
Average True Range | 0.26 |
RSI (14) | 15.25 |
ADX | 25.07 |
+DI | 29.66 |
-DI | 24.00 |
Chandelier Exit (Long, 3 ATRs) | 2.68 |
Chandelier Exit (Short, 3 ATRs) | 1.33 |
Upper Bollinger Bands | 1.36 |
Lower Bollinger Band | 0.32 |
Percent B (%b) | 0.25 |
BandWidth | 123.52 |
MACD Line | -0.57 |
MACD Signal Line | -0.71 |
MACD Histogram | 0.1371 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.64 | ||||
Resistance 3 (R3) | 0.64 | 0.62 | 0.63 | ||
Resistance 2 (R2) | 0.62 | 0.60 | 0.62 | 0.62 | |
Resistance 1 (R1) | 0.60 | 0.59 | 0.59 | 0.60 | 0.62 |
Pivot Point | 0.58 | 0.58 | 0.57 | 0.58 | 0.58 |
Support 1 (S1) | 0.56 | 0.56 | 0.55 | 0.56 | 0.53 |
Support 2 (S2) | 0.54 | 0.55 | 0.54 | 0.53 | |
Support 3 (S3) | 0.52 | 0.54 | 0.53 | ||
Support 4 (S4) | 0.52 |